BioNTech
NEWS
Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.
Studies are ongoing in Israel on whether a fourth dose of an mRNA vaccine offers additional protection. Although the data is still early, it suggests that it might not.
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
One of the big stories this week that even momentarily eclipsed COVID-19, was the landmark transplant of a genetically modified pig heart into a human male with terminal heart disease. For that and more research stories, read on.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.
JOBS
IN THE PRESS